Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

LC-MS/MS-based 4D Label-Free Proteomics Analysis of Bone Marrow Cells from ADO2 Mice

ABSTRACT: This project focuses on the global proteomic profiling of bone marrow cells (BMCs) in the ADO2 mouse model using LC-MS/MS-based 4D Label-Free Proteomics Analysis. The study aims to identify differentially expressed proteins and elucidate potential molecular mechanisms underlying osteopetrosis pathogenesis.

ORGANISM(S): Rattus Rattus

SUBMITTER: Minglin Ou

PROVIDER: PXD060536 | iProX | Wed Feb 05 00:00:00 GMT 2025

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Publications

SUGAR-seq reveals the transcriptome and N-linked glycosylation landscape of mononuclear phagocytes at single-cell resolution in a mouse model of autosomal dominant osteopetrosis type 2.

Sha Yu Y Huang Lingyu L Zhang Lei L Hou Xianliang X Mo Chune C Pan Cuiping C Chen Gengshuo G Luo Sha S Ou Minglin M

BMC biology 20250331 1

<h4>Background</h4>Heterozygous mutation of CLCN7 (R286W) is commonly found in patients with benign autosomal dominant osteopetrosis. However, there is no evidence from animal models to confirm that it is a disease mutation. And the characteristics of the bone marrow cell (BMC) landscape in osteopetrosis at the single-cell level are completely unknown till now.<h4>Results</h4>In this study, we generated the first autosomal dominant osteopetrosis type 2 (ADO2) mouse model with typical phenotypes ...[more]

PMID: 40165215

Similar Datasets

LC-MS/MS-based 4D Label-Free N-Glycosylation Proteomics Analysis of Bone Marrow Cells from ADO2 Mouse

Project description:This project aims to investigate N-linked glycosylation modifications in bone marrow cells (BMCs) of an autosomal dominant osteopetrosis type 2 (ADO2) mouse model carrying the Clcn7 (r284w) mutation. Using LC-MS/MS-based 4D Label-Free N-Glycosylation Proteomics Analysis, we identified significant alterations in the N-glycosylation landscape of ADO2 BMCs compared to wild-type (WT) controls. These findings provide insights into the role of glycosylation in ADO2 pathogenesis, particularly in mononuclear phagocytes.

2025-02-05 | PXD060501 |

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Project description:RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating patients who have hematologic cancer.

| 2004880 | ecrin-mdr-crc

Mouse bone marrow fibrosis LC-MS/MS

Project description:Bone marrow fibrosis (BMF) disrupts normal blood cell production, and excessive activation of the TGF-β signaling pathway is considered a key factor in the progression of the disease. Therefore, regulating TGF-β secretion is crucial for reversing fibrotic conditions. Histone deacetylase inhibitors (HDACis) are one such potential regulator, as they can influence TGF-β expression. In a previous study, we developed a selective HDAC6 inhibitor, J22352, targeting pulmonary fibrosis, but its effects on BMF were not previously examined. This study aimed to evaluate J22352's impact on bone marrow-derived myofibroblasts. We found that J22352 significantly reduced cell viability, triggered apoptosis, and suppressed extracellular matrix (ECM) accumulation. Through liquid chromatography-tandem mass spectrometry (LC-MS/MS), we identified 334 differentially expressed proteins (DEPs) linked to apoptosis, programmed cell death, ECM deposition, and collagen formation. These findings indicate that J22352 effectively mitigates BMF by inducing apoptosis and reducing ECM buildup. This study highlights J22352 as a promising selective HDAC6 inhibitor that could potentially slow BMF progression, offering new possibilities for clinical applications.

2025-08-25 | PXD055276 | Pride

Bone marrow niche

Project description:Bone marrow niche

| PRJNA429031 | ENA

Jiangu granules treated OVX rat cone bone 4D-LC-MS analysis

Project description:Postmenopausal osteoporosis (PMOP) is a disease with a high prevalence in postmenopausal women and is characterized by an imbalance in bone metabolism, reduced bone mass, and increased risk of fracture due to estrogen deficiency. Jiangu granules (JG) is a compound prescription used in traditional Chinese medicine to treat PMOP. We used a 4D label-free quantitative proteomics method to explore the potential therapeutic mechanism of JG in an ovariectomy (OVX) rats’ model.

2022-10-25 | PXD037316 | Pride

Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer

Project description:This phase II trial studies how well giving fludarabine phosphate, cyclophosphamide, tacrolimus, mycophenolate mofetil and total-body irradiation together with a donor bone marrow transplant works in treating patients with high-risk hematologic cancer. Giving low doses of chemotherapy, such as fludarabine phosphate and cyclophosphamide, and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer cells by stopping them from dividing or killing them. Giving cyclophosphamide after transplant may also stop the patient’s immune system from rejecting the donor’s bone marrow stem cells. The donated stem cells may replace the patient’s immune system cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body’s normal cells. Giving tacrolimus and mycophenolate mofetil after the transplant may stop this from happening

| 2008483 | ecrin-mdr-crc

bone marrow metagenome

Project description:Rashidi - 7D Bone Marrow

| PRJNA698990 | ENA

Dynamic alterations of dural and bone marrow B cells in an animal model of progressive MS

Project description:In multiple sclerosis (MS), the leptomeninges (LM) are populated with immune cell aggregates that correlate with disease progression. The impact of LM inflammation on the adjacent dura is largely unknown. Using a mouse model of MS that induces brain LM inflammation and age-dependent disease progression, we found that encephalitogenic T cells and B220high B cells accumulate substantially in the brain LM and parenchyma of both young and aged mice, while the adjacent dura remains relatively inert. We also observed a population of anti-CD20-resistant B220low B cells in the dura and bone marrow that virtually disappear at disease onset and accumulate in the brain of young mice concomitant with disease remission. In contrast, aged mice show a paucity of brain-resident B220low B cells at the expense of class-switched B220high B cells accompanied by severe, chronic disease. In summary, dynamic changes in the brain, LM, and dural B cells are associated with age-dependent disease severity in an animal model of progressive MS.

2025-09-05 | GSE299404 | GEO

SWATH-MS Analysis of Gfi1-mutant bone marrow neutrophils

Project description:This study investigates the proteomic alterations in bone marrow neutrophils isolated from 5-8 week old Gfi1+/-, Gfi1K403R/-, Gfi1R412X/-, and Gfi1R412X/R412X mice using the SWATH-MS technique. This dataset consists of 26 raw MS files, comprising 13 DDA (for spectral library generation)and 13 DIA (for SWATH) runs on a TripleTOF 5600 plus (SCIEX). Our findings revealed significant changes in the expression of neutrophil granule proteins and NADPH-oxidase complex components in Gfi1-mutant neutrophils.

2020-04-07 | PXD010943 | Pride

RNA-seq of CD11bhiLy6ChiLy6Glo bone marrow cells and CD11bmidLy6CmidLy6Glo bone marrow cells against CD11bloLy6CloLy6Glo bone marrow cells

Project description:RNA-seq of CD11bhiLy6ChiLy6Glo bone marrow cells and CD11bmidLy6CmidLy6Glo bone marrow cells against CD11bloLy6CloLy6Glo bone marrow cells

| PRJEB37925 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data